Soleno Therapeutics (SLNO) Shares Outstanding (Weighted Average) (2013 - 2026)
Soleno Therapeutics (SLNO) reported Shares Outstanding (Weighted Average) of $52.1 million for Q1 2026, up 12.8% year-over-year from $46.2 million in Q1 2025, and up 20604.0% on a QoQ basis from $251599.0 in Q4 2025.
Soleno Therapeutics (SLNO) has 14 years of Shares Outstanding (Weighted Average) data on file, last reported at $52.1 million in Q1 2026.
- Quarterly Shares Outstanding (Weighted Average) rose 12.8% year-over-year to $52.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $52.1 million (up 12.8% YoY) and the FY2025 annual result came in at $251599.0, down 99.37% from the prior year.
- Shares Outstanding (Weighted Average) rose to $52.1 million in Q1 2026 per SLNO's latest filing, from $251599.0 in the prior quarter.
- Across five years, Shares Outstanding (Weighted Average) topped out at $52.1 million in Q1 2026 and bottomed at $251599.0 in Q4 2025.
- The 5-year median for Shares Outstanding (Weighted Average) is $16.5 million (2023), against an average of $25.1 million.
- The widest annual swing landed in 2022, when Shares Outstanding (Weighted Average) soared 24423.49%; it then sank 99.37% in 2025.
- Tracing SLNO's Shares Outstanding (Weighted Average) over 5 years: stood at $8.4 million in 2022, then jumped by 96.4% to $16.5 million in 2023, then soared by 143.61% to $40.2 million in 2024, then slumped by 99.37% to $251599.0 in 2025, then soared by 20604.0% to $52.1 million in 2026.
- Per Business Quant, the three latest SLNO Shares Outstanding (Weighted Average) figures stand at $52.1 million (Q1 2026), $251599.0 (Q4 2025), and $50.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 177,333.76 Bn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 185,491.37 Bn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 100.00 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 55.66 Bn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 254.10 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 16.04 Bn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 132.89 Mn |
| 10 | Soleno Therapeutics | 2.76 Bn | 2.51 Bn | 93.41 Mn | 52.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 52.09 Mn |
| Dec 31, 2025 | 251,599.00 |
| Sep 30, 2025 | 50.02 Mn |
| Jun 30, 2025 | 48.34 Mn |
| Mar 31, 2025 | 46.18 Mn |
| Dec 31, 2024 | 40.18 Mn |
| Sep 30, 2024 | 38.92 Mn |
| Jun 30, 2024 | 37.42 Mn |
| Mar 31, 2024 | 36.21 Mn |
| Dec 31, 2023 | 16.49 Mn |
| Sep 30, 2023 | 11.44 Mn |
| Jun 30, 2023 | 9.94 Mn |
| Mar 31, 2023 | 9.45 Mn |
| Dec 31, 2022 | 8.40 Mn |
| Sep 30, 2022 | 9.42 Mn |
| Jun 30, 2022 | 7.35 Mn |
| Mar 31, 2022 | 5.33 Mn |
| Dec 31, 2021 | 34,241.00 |
| Sep 30, 2021 | 5.32 Mn |
| Jun 30, 2021 | 513,617.00 |
| Mar 31, 2021 | 513,617.00 |
| Dec 31, 2020 | 34,241.00 |
| Sep 30, 2020 | 6.02 Mn |
| Jun 30, 2020 | 513,617.00 |
| Mar 31, 2020 | 44.68 Mn |
| Dec 31, 2019 | 6.02 Mn |
| Sep 30, 2019 | 31.79 Mn |
| Jun 30, 2019 | 31.77 Mn |
| Mar 31, 2019 | 513,617.00 |
| Dec 31, 2018 | 6.02 Mn |
| Sep 30, 2018 | 21.43 Mn |
| Jun 30, 2018 | 19.94 Mn |
| Mar 31, 2018 | 19.53 Mn |
| Dec 31, 2017 | 6.02 Mn |
| Sep 30, 2017 | 485,121.00 |
| Jun 30, 2017 | 9.52 Mn |
| Mar 31, 2017 | 5.09 Mn |
| Dec 31, 2016 | 3.10 Mn |
| Sep 30, 2016 | 2.43 Mn |
| Jun 30, 2016 | 2.43 Mn |
| Mar 31, 2016 | 14.80 Bn |
| Dec 31, 2015 | 2.43 Mn |
| Sep 30, 2015 | 10.04 Mn |
| Jun 30, 2015 | 7.52 Mn |
| Mar 31, 2015 | 6.97 Mn |
| Dec 31, 2014 | 2.45 Mn |
| Sep 30, 2014 | 535,685.00 |
| Jun 30, 2014 | 535,685.00 |
| Mar 31, 2014 | 535,685.00 |
| Dec 31, 2013 | 535,648.00 |
| Sep 30, 2013 | 535,685.00 |